RxDoctor Payments DataLook up a doctor →

Armand Schachter, MD

Psychiatry · Birmingham, ALNPI 1295784312

Payments from drug & device makers

$757,993in general payments, 2019–2025

Across 2,019 payments — averaging $375.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$191K
  • AbbVie$135K
  • Axsome Therapeutics, Inc.$133K
  • Teva Pharmaceuticals USA, Inc.$84K
  • Johnson & Johnson$67K
  • Alkermes, Inc.$60K
  • plus $89K from 29 others

What the payments were for

  • Consulting fees$79,24110%
  • Speaking & faculty fees$578,71376%
  • Travel & lodging$68,5209%
  • Food & beverage$31,4894%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757,993 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$218,632
Medicare patients
395
Services billed
2,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl181$262,666
Invega SustennaPaliperidone Palmitate45$144,354
AuvelityDextromethorphan Hbr/Bupropion128$138,178
RexultiBrexpiprazole93$132,590
Abilify MaintenaAripiprazole28$78,883
AristadaAripiprazole Lauroxil15$45,963
TrintellixVortioxetine Hydrobromide87$43,295
SpravatoEsketamine Hcl27$21,420
CaplytaLumateperone Tosylate12$19,174
FetzimaLevomilnacipran Hcl36$17,438
Aripiprazole165$16,766
Desvenlafaxine Succinate ErDesvenlafaxine Succinate304$16,020
Fluphenazine Hcl125$15,476
QelbreeViloxazine Hcl36$12,666
Atomoxetine Hcl127$9,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$134,698$280,104217 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$190,623$211,473121 claims
Johnson & JohnsonInvega Sustenna, Spravato$67,079$165,77472 claims
Axsome Therapeutics, Inc.Auvelity$132,532$138,178128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$1,640$49,926104 claims
Alkermes, Inc.Aristada$60,099$45,96315 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$26,671$19,17412 claims
Supernus Pharmaceuticals, Inc.Qelbree$11,710$12,66636 claims
Teva Pharmaceuticals USA, Inc.Loxapine$83,683$4,04564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →